Back to User profile » Dr Erica Wegrzyn
Papers published by Dr Erica Wegrzyn:
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Opioid Taper Practices Among Clinicians
Persico AL, Bettinger JJ, Wegrzyn EL, Fudin J, Strassels SA
Journal of Pain Research 2021, 14:3353-3358
Published Date: 20 October 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The United States Drug Enforcement Administration and Prescription Opioid Production Quotas: An End Game of Eradication?
Schatman ME, Wegrzyn EL
Journal of Pain Research 2020, 13:2629-2631
Published Date: 19 October 2020
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Fentalogues
Persico AL, Wegrzyn EL, Fudin J, Schatman ME
Journal of Pain Research 2020, 13:2131-2133
Published Date: 20 August 2020
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A Randomized, Crossover, Pharmacokinetic and Adhesion Performance Study of a Lidocaine Topical System 1.8% During Physical Activity and Heat Treatment in Healthy Subjects
Fudin J, Wegrzyn EL, Greuber E, Vought K, Patel K, Nalamachu S
Journal of Pain Research 2020, 13:1359-1367
Published Date: 10 June 2020
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Pharmacogenetic guidance: individualized medicine promotes enhanced pain outcomes
Dragic LL, Wegrzyn EL, Schatman ME, Fudin J
Journal of Pain Research 2018, 11:37-40
Published Date: 22 December 2017
![Noteworthy comment: This is a very well written and supported focus paper. The topic is extremely timely and the content will create much desired discussion of the CDC opioid use guidelines.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Safety concerns with the Centers for Disease Control opioid calculator
Fudin J, Raouf M, Wegrzyn EL, Schatman ME
Journal of Pain Research 2018, 11:1-4
Published Date: 18 December 2017
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal disease
Mathew RO, Bettinger JJ, Wegrzyn EL, Fudin J
Journal of Pain Research 2016, 9:1191-1195
Published Date: 8 December 2016
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form
Fudin J, Raouf M, Wegrzyn EL
Journal of Pain Research 2016, 9:609-612
Published Date: 7 September 2016